Q3 2024 EPS Estimates for DENTSPLY SIRONA Inc. Lowered by Analyst (NASDAQ:XRAY)

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Research analysts at Barrington Research cut their Q3 2024 earnings per share estimates for DENTSPLY SIRONA in a research note issued on Thursday, August 1st. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will earn $0.47 per share for the quarter, down from their prior estimate of $0.53. Barrington Research currently has a “Outperform” rating and a $38.00 target price on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.98 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s Q4 2024 earnings at $0.60 EPS, FY2024 earnings at $1.98 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.55 EPS, Q3 2025 earnings at $0.56 EPS, Q4 2025 earnings at $0.64 EPS, FY2025 earnings at $2.25 EPS and FY2026 earnings at $2.55 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.01). The firm had revenue of $984.00 million for the quarter, compared to the consensus estimate of $993.61 million. DENTSPLY SIRONA had a negative net margin of 4.75% and a positive return on equity of 11.86%. The firm’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.51 earnings per share.

A number of other brokerages also recently issued reports on XRAY. Needham & Company LLC dropped their price target on shares of DENTSPLY SIRONA from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Evercore ISI cut their target price on shares of DENTSPLY SIRONA from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. The Goldman Sachs Group lowered their price target on DENTSPLY SIRONA from $34.00 to $30.00 and set a “neutral” rating on the stock in a report on Monday, May 6th. Piper Sandler reaffirmed a “neutral” rating and issued a $32.00 price objective (down previously from $35.00) on shares of DENTSPLY SIRONA in a report on Friday, May 3rd. Finally, Stifel Nicolaus lowered their target price on DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating on the stock in a report on Thursday, July 18th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.44.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY opened at $24.15 on Monday. The firm has a market cap of $5.01 billion, a P/E ratio of -54.89, a PEG ratio of 1.23 and a beta of 1.01. DENTSPLY SIRONA has a twelve month low of $23.94 and a twelve month high of $39.81. The company has a quick ratio of 0.97, a current ratio of 1.33 and a debt-to-equity ratio of 0.57. The company has a 50 day moving average of $26.05 and a 200 day moving average of $29.84.

DENTSPLY SIRONA Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 11th. Stockholders of record on Friday, September 27th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 2.65%. The ex-dividend date is Friday, September 27th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently -145.45%.

Insider Activity

In other news, Director Gregory T. Lucier bought 3,577 shares of DENTSPLY SIRONA stock in a transaction that occurred on Friday, May 31st. The stock was bought at an average cost of $27.95 per share, with a total value of $99,977.15. Following the acquisition, the director now owns 58,374 shares of the company’s stock, valued at approximately $1,631,553.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.52% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of XRAY. Parkside Financial Bank & Trust boosted its stake in shares of DENTSPLY SIRONA by 33.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,169 shares of the medical instruments supplier’s stock worth $42,000 after acquiring an additional 292 shares during the period. Wahed Invest LLC boosted its stake in DENTSPLY SIRONA by 9.3% in the 4th quarter. Wahed Invest LLC now owns 3,603 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 306 shares during the period. VisionPoint Advisory Group LLC boosted its stake in DENTSPLY SIRONA by 57.1% in the 4th quarter. VisionPoint Advisory Group LLC now owns 1,216 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 442 shares during the period. Raymond James Trust N.A. grew its holdings in DENTSPLY SIRONA by 4.9% during the 2nd quarter. Raymond James Trust N.A. now owns 9,658 shares of the medical instruments supplier’s stock valued at $241,000 after buying an additional 453 shares in the last quarter. Finally, LRI Investments LLC raised its position in shares of DENTSPLY SIRONA by 82.7% during the second quarter. LRI Investments LLC now owns 1,246 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 564 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.